DELIVER-HF Dapagliflozin Benefit Calculator

Clinical calculation support · Verify results before clinical use

Clinical decision support — illustrative estimate only. This calculator reproduces the simplified, non-validated estimation method in the supplied source file. It is not a validated individual risk calculator and should not be used to determine whether a patient should receive dapagliflozin.

Estimate treatment benefit

Enter patient characteristics to calculate the source model's illustrative 2-year estimates.

Illustrative model
DELIVER enrolled adults aged 40 years or older.
Must be greater than 40% for this tool.

About the DELIVER trial

DELIVER evaluated dapagliflozin 10 mg once daily versus placebo, added to usual therapy, in patients with heart failure and LVEF greater than 40%. The primary endpoint was worsening heart failure (unplanned hospitalization or an urgent visit for heart failure) or cardiovascular death.

Published trial results

OutcomeDapagliflozinPlacebo
Primary endpoint over median 2.3 years16.4%19.5%
Hazard ratio (95% CI)0.82 (0.73–0.92)

The trial-level event rates above are observed study results; they should not be interpreted as an individual's untreated baseline risk. The trial's hazard ratio also does not validate the adjustment formula used by this calculator.

What this calculator does

  • Starts with an assumed 20% 2-year baseline risk.
  • Applies the original source file's simplified adjustments for NT-proBNP, eGFR below 60, and NYHA class III/IV.
  • Caps the estimated baseline risk at 50% and applies an assumed treatment HR of 0.82 to derive nominal ARR and NNT.

Limitations and clinical use

  • This is a non-validated illustrative model, not a DELIVER-derived individual risk equation.
  • Age and LVEF are used for input eligibility checks but do not change the numerical estimate.
  • The formula does not incorporate all clinical variables, competing risks, follow-up differences, or uncertainty around the treatment effect.
  • The calculated NNT is sensitive to the assumed baseline risk and should not be treated as a trial-reported NNT.

Reference

Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387:1089–1098. doi:10.1056/NEJMoa2206286
Clinical disclaimer: This educational tool does not replace clinical assessment, current guidelines, prescribing information, or shared decision-making. Assess the patient's overall heart failure phenotype, renal function, volume status, contraindications, and treatment context before prescribing. The calculator's individualized numerical outputs are not clinically validated.